Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 291

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 19
Chunk 291
---
 share data)

                                                                                       Year ended December 31,                                                                      
                                                                                       2022                                         2023                      2024                  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Research and development, net                                                        $                                20,890      $             26,424      $             27,020  
  Marketing expenses                                                                                                       974                     1,924                     2,349  
  General and administrative                                                                                            10,272                     7,332                     6,673  
  Total operating loss                                                                                                  32,136                    35,680                    36,042  
  Financial expenses (income), net                                                                                       1,606                   ( 6,539                   ( 4,298  
  Loss before taxes on income                                                                                           33,742                    29,141                    31,744  
  Tax on income                                                                                                             20                        16                         6  
  Net loss                                                                                                              33,762                    29,157                    31,750  
  Net comprehensive loss                                                               $                                33,762      $             29,157      $             31,750  
  Net loss per share, basic and diluted                                                $                                ( 0.53      $             ( 0.42      $             ( 0.45  
  Weighted-average shares used in computing net loss per share, basic and diluted                                   63,534,875                69,377,922                69,927,566  

The accompanying notes are an integral part of
the consolidated financial statements.

F-5

ALPHA TAU MEDICAL LTD. AND ITS SUBSIDIARIES

CONSOLIDATED
STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS’ (DEFICIENCY) EQUITY

U. S. dollars in thousands (except share
and per share data)

                                                                                             Convertible Preferred                      Additional                                                             
                                                                                             shares                                     paid-in                      Accumulated                               
                                                                                             Shares                                     capital                      deficit                                   
  Balances as of January 1, 2022                                                                                        40,528,913      $               18,063       $                ( 52,840       ( 34,777  
  Exercise of Warrants to Ordinary shares                                                                               1,612,980                       3,335                         -                 3,335  
  Issuance of shares in connection with SPAC merger and PIPE financing